A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
==== IR spectroscopy ==== One case study investigated the formation of gaseous intermediates in the decomposition of CCl4 in the presence of steam over La2O3 using Fourier-transform infrared spectroscopy. This experiment produced useful information about the reaction mechanism, active site orientation, and about which species compete for the active site.
== Adverse effects == The most common adverse drug reactions (ADRs) are dose-related and arise from the effect of loop diuretics on diuresis and electrolyte balance. Common ADRs include: hyponatremia, hypokalemia, hypomagnesemia, dehydration, hyperuricemia, gout, dizziness, postural hypotension, syncope. The loss of magnesium as a result of loop diuretics has also been suggested as a possible cause of pseudogout (chondrocalcinosis). Infrequent ADRs include: dyslipidemia, increased serum creatinine concentration, hypocalcemia, rash. Metabolic alkalosis may also be seen with loop diuretic use. Ototoxicity (damage to the inner ear) is a serious, but rare ADR associated with use of loop diuretics. This may be limited to tinnitus and vertigo, but may result in deafness in serious cases. Loop diuretics may also precipitate kidney failure in patients concurrently taking an NSAID and an ACE inhibitor—the so-called "triple whammy" effect. Because furosemide, torsemide and bumetanide are technically sulfa drugs, there is a theoretical risk that patients sensitive to sulfonamides may be sensitive to these loop diuretics. This risk is stated on drug packaging inserts. However, the actual risk of crossreactivity is largely unknown and there are some sources that dispute the existence of such cross reactivity. In one study it was found that only 10% of patients with allergy to antibiotic sulfonamides were also allergic to diuretic sulfonamides, but it is unclear if this represents true cross reactivity or the nature of being prone to allergy.
=== Challenges === Despite its promise, relatively little silk has reached the clinic, and the reasons are specific. Foremost among them is variability. Silk is a farmed natural product, so its composition shifts with the silkworm strain, its diet and its rearing conditions, and this batch-to-batch variation is difficult to reconcile with the strict specifications required of a medical device. Processing introduces further variation: the duration of exposure to the dissolving salt and the amount of heat applied both affect the molecular weight of the regenerated protein, and with it the strength and degradation of the final product. Sterilisation presents a further difficulty, since standard autoclaving alters the structure of the protein, and a gentler method must be identified and validated for each format. Controlling the degradation rate precisely, scaling laboratory processes to industrial volumes, and meeting the regulatory requirements for an implanted device are each demanding in their own right. These engineering and manufacturing obstacles, rather than any deficiency in the biological performance of silk, are the main reason that most of it remains in the laboratory.
== Properties == Supercritical fluids generally have properties between those of a gas and of a liquid. In Table 1, the critical properties are shown for some substances that are commonly used as supercritical fluids.
Sources: en.wikipedia.org
== Economy and finances == After 1937, the economy of Aden continued to be largely dependent on the city's role as an entrepôt for east–west trade. During the course of 1955, 5,239 vessels called at Aden, making its harbour the second busiest in the world after New York. However, tourism declined over the last years of the Colony with the number of tourists landing dropping by 37% from 204,000 in 1952 to 128,420 in 1966. At the end of British rule in 1967, the main revenues of the Colony were the Port Trust with an annual gross revenue of £1.75 million (2014 prices: £28.4 million) and the BP refinery which made direct payments to the Aden Government of £1.135 million (2014 prices: £18.4 million). In 1956, Aden Colony had a revenue of £2.9 million (approximately £65 million in 2014 prices). This was equivalent to around £58 per capita, one of the highest per head revenue earners amongst Britain's smaller colonies behind only the Falkland Islands, Brunei and Bermuda. However, the benefit to the United Kingdom of this was tempered by their commitments to the Aden protectorates which had revenue per capita of only 2.5 pence (only 23p in 2014 prices). By the time British rule was ending the Federation of South Arabia, of which the Colony was a part, was receiving £12.6 million (£209 million in 2014) from the British government to support its 1966–67 Budget.
=== 68Ga radiolabeling === 68Ga-Trivehexin is a radioactive drug. The radioactive atom, gallium-68 (68Ga), decays with a half-life of approximately 68 min to the stable isotope zinc-68 (68Zn), to 89% by β+ decay whereby a positron with a maximum kinetic energy of 1.9 MeV is emitted (the remaining 11% are EC decays). Due to the short half-life, 68Ga-Trivehexin can not be manufactured long before use but the 68Ga has to be introduced into the molecule shortly before application. This process is referred to as radiolabeling, and is done by complexation of the trivalent cation 68GaIII by the TRAP chelator in Trivehexin. 68GaIII is usually obtained from a dedicated mobile radionuclide source, a Gallium-68 generator, in form of a solution in dilute (0.04–0.1 M) hydrochloric acid (frequently and imprecisely referred to as "68Ga chloride solution in HCl" despite it contains no species with a Ga–Cl bond but [68Ga(H2O)6]3+ complex hydrate cations). For radiolabeling, the pH of the 68Ga containing generator eluate has to be raised from its initial value (depending on HCl concentration, pH 1–1.5) to pH 2–3.5 using suitable buffers, such as sodium acetate. Then, Trivehexin (5–10 nmol) is added to the buffered 68Ga-containing solution, and the mixture is briefly heated to 50–100 °C (usually 2–3 min) to finalize the complexation reaction.
In 1808, Andrew Johnson, the United States' future 17th President, was born at Casso's Inn in Raleigh. The city's first water supply network was completed in 1818, although due to system failures, the project was abandoned. In 1817, the Episcopal Diocese of North Carolina was established and headquartered in Raleigh. In 1819, Raleigh's first volunteer fire company was founded, followed in 1821 by a full-time fire company. In 1831, a fire destroyed the North Carolina State House. Two years later, reconstruction began with quarried gneiss being delivered by the first railroad in the state. Raleigh celebrated the completion of the new State Capitol and new Raleigh & Gaston Railroad Company in 1840. The first State Fair was held near Raleigh in 1853. The first institution of higher learning in Raleigh, Peace College, was established in 1857. Raleigh's Historic Oakwood contains many houses from the 19th century that are still in good condition. North Carolina seceded from the Union during the American Civil War on May 20, 1861. After the war began, Governor Zebulon Baird Vance ordered the construction of breastworks around the city as protection from Union troops. The North Carolina State School for the Blind and Deaf, currently known as the Governor Morehead School, served as Raleigh's arsenal. Near the end of the Civil War, Governor Vance arranged his evacuation to avoid capture as Union General William Sherman's forces approached the city. Before leaving, Vance met with former governors Graham and Swain to draft a letter of surrender for Raleigh.
Working with E. R. Giblett in 1972, Ammann described the first patient with purine nucleoside phosphorylase deficiency in association with a unique genetic profile that included depressed T-cell immunity with normal levels of immunoglobulins. The resulting publication was listed as one of the 500 most widely cited articles in 1984. Ammann's discovery represented an essential step to understanding new treatments for immunodeficiency diseases and developing drugs that could interfere with the immune response.
=== European Union === In 2000, the European Union (EU) enacted similar legislation, Regulation(EC) No 141/2000, which refers to drugs developed to treat rare diseases to as "orphan medicinal products". The EU's definition of an orphan condition is broader than that of the US, in that it also covers some tropical diseases that are primarily found in developing nations. Orphan drug status granted by the European Commission gives marketing exclusivity in the EU for 10 years after approval. The EU's legislation is administered by the Committee on Orphan Medicinal Products of the European Medicines Agency (EMA). In late 2007 the FDA and EMA agreed to use a common application process for both agencies to make it easier for manufacturers to apply for orphan drug status but, while continuing two separate approval processes.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.